MYSM1-mediated epigenetic modification dysregulation leads to immunosuppression and secondary infections in sepsis
Open Access
- 12 February 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 22 (2) , e1013935
Abstract
Sepsis is a life-threatening condition characterized by a dysregulated immune response to infection, often leading to organ dysfunction and even death. During the recovery phase of sepsis, patients frequently exhibit impaired antimicrobial function of immune cells, which exacerbates the state of immunosuppression and increases the risk of secondary infections. However, therapeutic strategies targeting sepsis-induced immunosuppression have yet to achieve breakthrough progress, with the core challenge lying in the significant gaps in understanding the molecular mechanisms underlying immunosuppression. In this study, we integrated clinical samples, mouse models, and molecular mechanisms to reveal that the reduction in macrophage function and epigenetic dysregulation, particularly histone ubiquitination, are central drivers of sepsis-induced immunosuppression. Further investigation demonstrated that MYSM1, a deubiquitinase, plays a pivotal role in regulating this ubiquitination process. Targeted deletion of the N-terminal domain of MYSM1 markedly enhances the inflammatory response during the early phase of secondary infection in sepsis, facilitating bacterial clearance and significantly mitigating tissue damage in the late phase of secondary infection, thereby improving the survival outcomes in mice. Overall, our study elucidates the role of MYSM1-mediated dysregulation of epigenetic modifications in the immune response during the late phase of sepsis, providing a novel therapeutic approach for addressing sepsis-related immune dysfunction.Keywords
Funding Information
- Hubei Provincial Key Research and Development Program (2023BCB017)
- National Key R&D Program Special Project on Technology Response to Active Health and Population Aging (2023YFC3604700)
- National Key R&D Program Special Project on Diagnostic and Therapeutic Equipment and Biomedical Technology (2022YFC2401900)
- National Natural Science Foundation of China (32400131)
This publication has 57 references indexed in Scilit:
- LncRNA MALAT1 Regulates USP22 Expression Through EZH2-Mediated H3K27me3 Modification to Accentuate Sepsis-Induced Myocardial DysfunctionCardiovascular Toxicology, 2022
- USP38 Couples Histone Ubiquitination and Methylation via KDM5B to Resolve InflammationAdvanced Science, 2020
- Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysisIntensive Care Medicine, 2020
- Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shockBiochemical Pharmacology, 2018
- Histone H3 phosphorylation – A versatile chromatin modification for different occasionsBiochimie, 2012
- Impaired CD4+ T‐cell proliferation and effector function correlates with repressive histone methylation events in a mouse model of severe sepsisEuropean Journal of Immunology, 2010
- Increasing evidence that the risks of rhAPC may outweigh its benefitsIntensive Care Medicine, 2007
- Unraveling Severe SepsisJAMA, 2003
- Interferon Gamma-1b in the Treatment of Compensatory Anti-inflammatory Response SyndromeArchives of internal medicine (1960), 1997
- Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis SyndromeJAMA, 1995